Inventiva S.A. (NASDAQ:IVA) was up 6.9% on Wednesday . The company traded as high as $17.25 and last traded at $16.84. Approximately 57,491 shares were traded during trading, an increase of 75% from the average daily volume of 32,897 shares. The stock had previously closed at $15.75.
Separately, Chardan Capital reiterated a “neutral” rating on shares of Inventiva in a research note on Monday, September 21st.
The firm’s 50 day moving average price is $13.15.
Inventiva SA, a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment.
Featured Story: What is the yield curve?
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.